Viatris Inc

Overview

Viatris Inc. is a global pharmaceutical company whose portfolio includes generics, complex generics, established branded medicines and innovative medicines across a range of therapeutic areas. Its portfolio includes more than 1,400 approved molecules, with areas such as cardiovascular medicine, eye care and oncology.[1]+2 The company’s stated purpose is “to empower people worldwide to live healthier at every stage of life.” [2]

Viatris operates in more than 165 countries and territories, employs more than 30,000 people, and reports supplying medicines to approximately 1 billion patients annually.[1][2] For the year ended December 31, 2025, it reported total revenues of approximately $14.3 billion.[4] The company launched in November 2020 through the combination of Mylan and Pfizer’s Upjohn business.[5] [1]+4

Products & services

Viatris’ products span branded and generic medicines, including complex generics. Named products include Lipitor, Norvasc, EpiPen, Lyrica, Viagra, Creon, Celebrex, Zoloft and Effexor, alongside products such as Yupelri, Dymista, Amitiza and Xanax. Its complex generics include Breyna, a generic version of Symbicort; Wixela Inhub, a generic version of Advair Diskus; glatiramer acetate injection, a generic version of Copaxone; and generic iron sucrose injection. The company describes complex medicines as involving factors such as the active ingredient, formulation, delivery route or a drug-device combination.[6]+2

Specific examples include Yupelri (revefenacin), an inhalation solution for maintenance treatment of COPD and a once-daily nebulized bronchodilator; Viatris handles its commercial manufacturing and commercialization, while Theravance co-promotes it in the hospital channel. Iron Sucrose Injection, USP, is an intravenous iron replacement for iron-deficiency anemia in adults and children aged two and older with chronic kidney disease; disclosed vial strengths are 50 mg/2.5 mL, 100 mg/5 mL and 200 mg/10 mL.[9][10]

In FY2025, brands generated $9.184 billion of Viatris’ $14.250 billion in net sales, and generics generated $5.066 billion—about 64% and 36%, respectively, calculated from the reported amounts. The company also describes research and development, clinical and regulatory work, licensing, product launches and lifecycle management as capabilities supporting its medicines; the reviewed disclosures do not identify a separate general fee-for-service offering.[11]+2 [6]+9

Geographic presence

Viatris operates in more than 165 countries and territories, with more than 30,000 employees. Its geographic segments are Developed Markets, primarily North America and Europe; Greater China, comprising mainland China, Taiwan and Hong Kong; JANZ, comprising Japan, Australia and New Zealand; and Emerging Markets, spanning more than 125 countries across Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the company’s ARV franchise.[14][15]

In fiscal 2025, net sales were $8,514.0 million in Developed Markets (59.7% of total), $2,332.5 million in Greater China (16.4%), $1,193.8 million in JANZ (8.4%) and $2,210.1 million in Emerging Markets (15.5%).[4] In the first half of 2026, the respective figures were $4,214.5 million (58.1%), $1,393.9 million (19.2%), $569.5 million (7.8%) and $1,077.7 million (14.9%).[16] These disclosures report sales by segment rather than by individual country.

The company lists its address in Canonsburg, Pennsylvania, and identifies global centers in Pittsburgh, Pennsylvania; Shanghai, China; and Hyderabad, India.[17][18] Viatris reports 27 manufacturing, packaging and distribution sites across five continents; the cited information does not provide a geographic employee breakdown or a site-by-site facility list.[19] [14]+12

Business segments

Viatris reports four geographic/market-based segments. In FY2025, Developed Markets—primarily North America and Europe—contributed approximately 59.7% of net sales; Greater China (mainland China, Taiwan and Hong Kong), 16.4%; JANZ (Japan, Australia and New Zealand), 8.4%; and Emerging Markets (developing markets across Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the ARV franchise), 15.5%.[15][4] These shares are calculated from segment net sales totaling $14.2504 billion for the year ended December 31, 2025.[4] [15]+5

Company history

Mylan was founded in 1961 in West Virginia, initially distributing medicines to rural pharmacies and physicians. In 2007 it expanded its manufacturing presence in India through its acquisition of a controlling stake in Matrix Laboratories. Pfizer established Upjohn as a standalone business in 2018, drawing on its Established Medicines division.[20][21]

Mylan and Pfizer announced plans in July 2019 to combine Mylan with Pfizer’s Upjohn business, and announced Viatris as the new company name that November. Viatris was formed and launched on November 16, 2020, through the combination of Mylan and Upjohn.[22]+2

In 2021, Viatris announced FDA approval of Semglee as the first interchangeable biosimilar under the 351(k) pathway, followed by its commercial launch later that year. In 2022, it completed the transfer of its biosimilars portfolio to Biocon Biologics. In 2024, the company continued reshaping its portfolio, acquiring global rights to Idorsia’s selatogrel and cenerimod assets and completing divestitures that included its India API, OTC and women’s healthcare businesses.[25]+4 [24]+9

Sources

• Viatris Inc — Full financial report (2025 Y)
  15 citations

  [1][2][4][6][7][9][10][11][12][13][14][15][17][19][27]
• www.viatris.com[3]
• newsroom.viatris.com[5]
• Viatris Inc — Press release (2026 Q 2)[8]
• Viatris Inc — Full financial report (2026 Q 2)[16]
• www.viatris.com[18]
• www.viatris.com[20]
• www.viatris.com[21]
• newsroom.viatris.com[22]
• newsroom.viatris.com[23]
• Viatris Inc — Full financial report (2020 Y)[24]
• Viatris Inc — Full financial report (2021 Y)[25]
• Viatris Inc — Full financial report (2022 Y)[26]
• Viatris Inc — Full financial report (2024 Y)[28][29]